Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:country |
gptkb:China
|
| gptkbp:founded |
2000
|
| gptkbp:headquarters_location |
gptkb:Beijing
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sino Biopharmaceutical
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:keyPerson |
Tse Ping
Terence Tse |
| gptkbp:listedOn |
gptkb:Hang_Seng_Index
|
| gptkbp:market |
gptkb:Asia
gptkb:Europe gptkb:America |
| gptkbp:numberOfEmployees |
20,000+
|
| gptkbp:parentCompany |
gptkb:Chia_Tai_Group
|
| gptkbp:products |
oncology drugs
cardiovascular drugs hepatitis drugs respiratory system drugs |
| gptkbp:researchInterest |
oncology
hepatology cardiovascular diseases |
| gptkbp:revenue |
CNY 30.3 billion (2022)
|
| gptkbp:stockExchange |
gptkb:Hong_Kong_Stock_Exchange
|
| gptkbp:stockSymbol |
1177.HK
|
| gptkbp:subsidiary |
CT Tianqing Pharmaceutical Group
Beijing Tide Pharmaceutical |
| gptkbp:website |
http://www.sinobiopharm.com/
|
| gptkbp:bfsParent |
gptkb:WuXi_Biologics
|
| gptkbp:bfsLayer |
7
|